US2014348764A1PendingUtilityA1

Methods of Blocking Ultraviolet Radiation and Promoting Skin Growth Using Terpenes and Terpenoids

40
Assignee: LABUDA IVICAPriority: Sep 17, 2009Filed: Jun 3, 2014Published: Nov 27, 2014
Est. expirySep 17, 2029(~3.2 yrs left)· nominal 20-yr term from priority
Inventors:Ivica LabudaFredric Jay Burns
A61P 17/02A61K 8/9789A61K 31/122A61Q 17/04A61K 8/35A61K 31/015A61K 31/12A61K 8/31A61K 48/00A61K 8/9794A61Q 19/08
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods of treating humans and animals with terpenes and terpenoids in order to rejuvenate the skin and increase the protective layer against irradiation by ultraviolet radiation (UVR). More specifically it provides terpenes and terpenoids as ingredients that work as persistent UVR blockers. Terpenes and terpenoid compounds support the growth of skin, skin tissue and keratinocytes and additional UVR-blocking by reason of increased stratum corneum thickness and loricrin content. Both terpenes and terpenoids may be applied topically or orally at oral or topical concentrations from about 6 mg to about 600 mg per kilogram of body weight per day effective to stimulate growth of the skin layer and prevent damage from ultraviolet radiation (UVR).

Claims

exact text as granted — not AI-modified
1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . A method of rejuvenating the skin comprising administering a terpene or a terpenoid. 
     
     
         11 . A method according to  claim 10  wherein the terpene or terpenoid is administered prior to exposure to UVR. 
     
     
         12 . A method according to  claim 10  wherein the terpene or terpenoid is administered at least one time per day. 
     
     
         13 . A method according to  claim 10  wherein the terpene or terpenoid is selected from the group consisting of beta-damascenone, nootkatone, and d-limonene. 
     
     
         14 . A method according to  claim 10  wherein the terpene or terpenoid is administered orally. 
     
     
         15 . A method according to  claim 10  wherein the terpene or terpenoid is administered topically. 
     
     
         16 . A method according to  claim 10  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to reduce the amount of cutaneous inflammation and erythema present in the skin of subjects receiving the terpene or terpenoid compared to the amount of cutaneous inflammation and erythema present in the skin of subjects not receiving the terpene or terpenoid when both subjects or both sets of subjects are exposed to the same dosage of UVR. 
     
     
         17 . A method according to  claim 10  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to increase epidermal cell proliferation and increase keratin production in the skin of subjects receiving the terpene or terpenoid compared to the amount of epidermal cell proliferation and keratin production present in the skin of subjects not receiving the terpene or terpenoid when both subjects or both sets of subjects are exposed to the same dosage of UVR. 
     
     
         18 . A method according to  claim 10  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to alter the expression of one or more gene products selected from the group consisting of NFKappaB, COX1, COX2, MAPKS, PGE2, ODC, protein kinase C, INOS, PI3-AKT, TNF-A, AP1, NRF2, KEAP1 and IKappa kinase. 
     
     
         19 . A method of increasing keratin production comprising administering a terpene or a terpenoid. 
     
     
         20 . A method according to  claim 19  wherein the terpene or terpenoid is administered prior to exposure to UVR. 
     
     
         21 . A method according to  claim 19  wherein the terpene or terpenoid is administered at least one time per day. 
     
     
         22 . A method according to  claim 19  wherein the terpene or terpenoid is selected from the group consisting of beta-damascenone, nootkatone, and d-limonene. 
     
     
         23 . A method according to  claim 19  wherein the terpene or terpenoid is administered orally. 
     
     
         24 . A method according to  claim 19  wherein the terpene or terpenoid is administered topically. 
     
     
         25 . A method according to  claim 19  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to reduce the amount of cutaneous inflammation and erythema present in the skin of subjects receiving the terpene or terpenoid compared to the amount of cutaneous inflammation and erythema present in the skin of subjects not receiving the terpene or terpenoid when both subjects or both sets of subjects are exposed to the same dosage of UVR. 
     
     
         26 . A method according to  claim 19  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to increase epidermal cell proliferation and increase keratin production in the skin of subjects receiving the terpene or terpenoid compared to the amount of epidermal cell proliferation and keratin production present in the skin of subjects not receiving the terpene or terpenoid when both subjects or both sets of subjects are exposed to the same dosage of UVR. 
     
     
         27 . A method according to  claim 19  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to alter the expression of one or more gene products selected from the group consisting of NFKappaB, COX1, COX2, MAPKS, PGE2, ODC, protein kinase C, INOS, PI3-AKT, TNF-A, AP1, NRF2, KEAP1 and IKappa kinase. 
     
     
         28 . A method of promoting wound healing comprising administering a terpene or a terpenoid. 
     
     
         29 . A method according to  claim 28  wherein the terpene or terpenoid is administered prior to exposure to UVR. 
     
     
         30 . A method according to  claim 28  wherein the terpene or terpenoid is administered at least one time per day. 
     
     
         31 . A method according to  claim 28  wherein the terpene or terpenoid is selected from the group consisting of beta-damascenone, nootkatone, and d-limonene. 
     
     
         32 . A method according to  claim 28  wherein the terpene or terpenoid is administered orally. 
     
     
         33 . A method according to  claim 28  wherein the terpene or terpenoid is administered topically. 
     
     
         34 . A method according to  claim 28  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to reduce the amount of cutaneous inflammation and erythema present in the skin of subjects receiving the terpene or terpenoid compared to the amount of cutaneous inflammation and erythema present in the skin of subjects not receiving the terpene or terpenoid when both subjects or both sets of subjects are exposed to the same dosage of UVR. 
     
     
         35 . A method according to  claim 28  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to increase epidermal cell proliferation and increase keratin production in the skin of subjects receiving the terpene or terpenoid compared to the amount of epidermal cell proliferation and keratin production present in the skin of subjects not receiving the terpene or terpenoid when both subjects or both sets of subjects are exposed to the same dosage of UVR. 
     
     
         36 . A method according to  claim 28  wherein the terpene or terpenoid is administered in a dosage and in amounts sufficient to alter the expression of one or more gene products selected from the group consisting of NFKappaB, COX1, COX2, MAPKS, PGE2, ODC, protein kinase C, INOS, PI3-AKT, TNF-A, AP1, NRF2, KEAP1 and IKappa kinase. 
     
     
         37 . (canceled) 
     
     
         38 . (canceled) 
     
     
         39 . (canceled)

Join the waitlist — get patent alerts

Track US2014348764A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.